Creative Planning’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$240M Buy
1,103,490
+59,677
+6% +$13.2M 0.16% 67
2025
Q4
$239M Buy
1,043,813
+73,670
+8% +$16.8M 0.17% 64
2025
Q3
$225M Buy
970,143
+131,060
+16% +$26.7M 0.17% 66
2025
Q2
$156M Sell
839,083
-3,943
-0.5% -$733K 0.13% 73
2025
Q1
$177M Buy
843,026
+81,953
+11% +$15.9M 0.17% 67
2024
Q4
$135M Buy
761,073
+10,262
+1% +$1.89M 0.13% 73
2024
Q3
$147M Buy
750,811
+33,225
+5% +$6.2M 0.15% 69
2024
Q2
$123M Buy
717,586
+2,787
+0.4% +$462K 0.13% 74
2024
Q1
$130M Buy
714,799
+31,489
+5% +$5.43M 0.14% 70
2023
Q4
$106M Buy
683,310
+17,978
+3% +$2.62M 0.2% 67
2023
Q3
$99.2M Buy
665,332
+54,826
+9% +$8.05M 0.13% 75
2023
Q2
$82.3M Buy
610,506
+1,254
+0.2% +$184K 0.11% 85
2023
Q1
$97.1M Buy
609,252
+16,426
+3% +$2.51M 0.14% 76
2022
Q4
$95.8M Buy
592,826
+134,121
+29% +$20.6M 0.14% 73
2022
Q3
$61.6M Buy
458,705
+2,433
+0.5% +$349K 0.11% 87
2022
Q2
$69.9M Buy
456,272
+24,906
+6% +$3.81M 0.12% 83
2022
Q1
$69.9M Buy
431,366
+23,152
+6% +$3.36M 0.11% 81
2021
Q4
$55.3M Buy
408,214
+10,382
+3% +$1.23M 0.09% 91
2021
Q3
$42.9M Buy
397,832
+4,143
+1% +$473K 0.08% 103
2021
Q2
$44.3M Sell
393,689
-54,720
-12% -$6.16M 0.08% 99
2021
Q1
$48.5M Buy
448,409
+8,904
+2% +$952K 0.1% 87
2020
Q4
$47.1M Buy
439,505
+18,327
+4% +$1.76M 0.1% 86
2020
Q3
$36.9M Buy
421,178
+35,371
+9% +$3.33M 0.1% 86
2020
Q2
$37.9M Buy
385,807
+30,050
+8% +$2.65M 0.11% 78
2020
Q1
$27.1M Sell
355,757
-9,873
-3% -$841K 0.1% 87
2019
Q4
$32.4M Sell
365,630
-7,742
-2% -$643K 0.1% 88
2019
Q3
$28.3M Sell
373,372
-2,431
-0.6% -$167K 0.09% 93
2019
Q2
$27.3M Buy
375,803
+39,427
+12% +$3.1M 0.09% 92
2019
Q1
$27.1M Buy
336,376
+20,721
+7% +$1.7M 0.1% 85
2018
Q4
$29.1M Buy
315,655
+13,932
+5% +$1.23M 0.12% 73
2018
Q3
$28.5M Buy
301,723
+15,702
+5% +$1.49M 0.11% 79
2018
Q2
$26.5M Buy
286,021
+18,377
+7% +$1.79M 0.1% 81
2018
Q1
$25.3M Buy
267,644
+6,521
+2% +$716K 0.1% 80
2017
Q4
$25.3M Buy
261,123
+21,549
+9% +$2.03M 0.11% 79
2017
Q3
$21.3M Buy
239,574
+6,527
+3% +$497K 0.1% 90
2017
Q2
$16.9M Sell
233,047
-9,300
-4% -$625K 0.09% 92
2017
Q1
$15.8M Sell
242,347
-9,565
-4% -$601K 0.09% 93
2016
Q4
$15.8M Sell
251,912
-4,391
-2% -$268K 0.1% 95
2016
Q3
$16.2M Buy
256,303
+20,173
+9% +$1.31M 0.1% 92
2016
Q2
$14.6M Buy
236,130
+47,103
+25% +$2.87M 0.11% 87
2016
Q1
$10.8M Sell
189,027
-2,417
-1% -$135K 0.08% 95
2015
Q4
$11.3M Buy
191,444
+16,011
+9% +$922K 0.09% 96
2015
Q3
$9.55M Buy
175,433
+16,401
+10% +$1.07M 0.08% 99
2015
Q2
$10.7M Buy
159,032
+35,032
+28% +$2.29M 0.1% 94
2015
Q1
$7.26M Buy
124,000
+10,315
+9% +$623K 0.07% 118
2014
Q4
$7.44M Buy
113,685
+9,425
+9% +$594K 0.08% 111
2014
Q3
$6.02M Sell
104,260
-8,000
-7% -$444K 0.07% 120
2014
Q2
$6.34M Buy
112,260
+3,658
+3% +$192K 0.08% 107
2014
Q1
$5.58M Buy
108,602
+26,648
+33% +$1.35M 0.08% 101
2013
Q4
$4.33M Buy
81,954
+5,196
+7% +$255K 0.07% 106
2013
Q3
$3.43M Buy
76,758
+986
+1% +$43.7K 0.07% 100
2013
Q2
$3.13M Buy
+75,772
New +$3.31M 0.07% 96

Other funds holding ABBV

Creative Planning's ABBV Position: Q1 2026 in Review

Creative Planning increased its AbbVie (ABBV) stake by 5.7% in Q1 2026, buying an estimated $13.2M and bringing the position to 1,103,490 shares worth $240M. The position accounts for 0.16% of the portfolio, ranked #67.

Creative Planning first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Creative Planning held 1,103,490 shares of AbbVie worth $240M as of Q1 2026.
  • Creative Planning bought 59,677 AbbVie shares in Q1 2026, an estimated $13.2M.
  • AbbVie made up 0.16% of Creative Planning's portfolio in Q1 2026, its #67 holding.
  • Creative Planning first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.